1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址：

https://www.keaipublishing.com/en/journals/pharmacoeconomics-and-policy/

4、投稿系统：

https://www.editorialmanager.com/pharp

5、官网邮箱：pandp@mail.xjtu.edu.cn

ppeditor@xjtu.edu.cn（公众号信息）

6、官网电话：029-82667978

029-88960092（公众号信息）

7、出刊日期：季刊，一年出版4期。

2024年6月24日星期一

西交大新刊| Pharmacoeconomics and Policy

《药物经济与政策（英文）》欢迎您的投稿！

【微信公众号“西安交通大学期刊网（xjtujour）”信息】

西安交通大学期刊网 2024-06-18 20:13 陕西

新刊上线

Pharmacoeconomics and Policy (P&P)

期刊及团队介绍

Pharmacoeconomics and Policy (P&P)（中文刊名：《药物经济与政策（英文）》，ISSN 2950-2667）由西安交通大学主办，季刊。期刊聚焦国内外药物经济学、卫生技术评估、人工智能等颠覆性技术驱动的创新医疗技术和药械产品评价、医药卫生政策等前沿领域。期刊刊发范围包括基础研究、创新理论、前沿方法与实际应用研究、关键技术与指标体系开发、基于真实世界的实证研究，以及医疗保险、药物政策、医院管理等交叉实践问题的研究论文、综述、评论、系列报道、快讯以及个人观点等。P&P旨在提高我国在药物经济与政策、卫生技术评估等领域的学术竞争力和国际影响力；创立具有自主知识产权的高水平英文期刊；填补我国在上述领域国际期刊的空白；助力我国相关研究向前迈进，打造创新性研究成果国际交流的高端学术平台。

P&P由复旦大学公共卫生学院胡善联教授和北京大学博雅特聘教授刘国恩担任荣誉主编。主编由西安交通大学药学院副院长、国际药物经济学与结果研究学会（International Society for Pharmacoeconomics and Outcomes Research，ISPOR）中国西北分会主席方宇教授担任，共同主编为美国杜兰大学公共卫生与热带病学院全球卫生政策与管理系副主任施李正教授。编委会由药物经济学与药物政策领域多位具有国际影响力的高水平学者组成。

荣誉主编

胡善联教授

刘国恩 教授

主编

方宇 教授

联合主编

施李正 教授

征稿范围

P&P刊发范围包括但不限于：药物经济学、药品定价与创新支付、医药卫生政策、药品安全与合理使用、卫生技术评估、药事管理、创新药械评价、药物流行病学、真实世界研究、药械监管科学、卫生经济评价、健康结局研究、疫苗经济学........

我们热烈欢迎您的关注及投稿！

期刊主页：

https://www.keaipublishing.com/en/journals/pharmacoeconomics-and-policy/

投稿网址：

https://www.editorialmanager.com/pharp/default2.aspx

邮  箱：ppeditor@xjtu.edu.cn

电  话：029-88960092

作者指南Guide for Authors

【官网信息】

INTRODUCTION

Types of paper

Full-length/Research Article

A complete report on original research and/or clinical studies

A structured abstract is required.

A clear structure is required, which should contain but not confined to the following sections:

Introduction

Methods

Results

Discussion

Conclusions

Authors' contribution (For details please visit the link.)

Ethic statement

COI

acknowledgments/clarification)

Bibliography

Appendices (including multimedia components)

Details guide to the article structure

Review Article

A substantial overviews present a complete overview of the state of the art with a comprehensive bibliography, generally, also contains a table of contents. It should cover topics that have seen significant development or progress in recent years, with comprehensive depth and a balanced perspective. Review articles should NOT include unpublished material such as unpublished/original data, submitted manuscripts, or personal communication.

Editorial (Word limit: 2,000)

Generally from the (guest) editor of the publication. Can be Foreword, Editorial, Guest Editorial, Preface, etc.

Short Communication (Word limit: 1,500)

Short report or announcement of research, usually claiming certain results, which present original and significant material for rapid dissemination. Short Communications are expected to have a higher than average impact on the field rather than report on incremental research.

Case Report (Word limit: 1,500)

Case Reports (CR) are brief reports of individual patients or small cohorts reporting novel findings of unexpected clinical significance. They are peer-reviewed articles under 1500 words in length. Methods and additional figures and display items may be included in the Supplementary Information.

Letter to the Editor (Word limit: 2,000;)

Any items of interest to the wide audience of the publication. The items includes a letter to the editor commenting on previously published articles or a reply to the letter. (The letter or reply needs a "refers-to" DOI or PII number; or argumentative communication, like papers in a discussion, or commentaries, etc.(Subsequent discussion papers need a "refers-to" DOI or PII number).

Perspective (Word limit: 3,000)

An article presents a new and unique viewpoint on existing problems, fundamental concepts, or prevalent notions on a specific topic, propose and support a new hypothesis, or discuss the implications of a newly implemented innovation. Perspective pieces may focus on current advances and future directions on a topic and may include original data as well as personal opinion. As a guideline, Perspective should not normally exceed 3,000 words. Perspectives allow up to 30 references; citations should be selective. Perspectives should include no more than 4 display items (figures, tables and/or boxes).

Policy Forum (Word limit: 2,000, 1 figure, and up to 10 references)

Policy Forums present issues related to pharmacoeconomics and HTA that have policy implications.

……

更多详情：

https://www.keaipublishing.com/en/journals/pharmacoeconomics-and-policy/guide-for-authors/